Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

Abstract Background/Objective We report the first analysis of an extended half‐life recombinant factor IX, nonacog beta pegol (N9‐GP), in previously untreated patients (PUPs) and minimally treated patients with hemophilia B. Methods Paradigm 6 (Safety and Efficacy of Nonacog Beta Pegol [N9‐GP] in Pr...

Full description

Bibliographic Details
Main Authors: Anthony K. Chan, Jayanthi Alamelu, Chris Barnes, Ampaiwan Chuansumrit, May‐Lill Garly, Rikke Medom Meldgaard, Guy Young
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
factor IX
hemophilia B
nonacog beta pegol
previously untreated patients
prophylaxis
recombinant proteins
Online Access:https://doi.org/10.1002/rth2.12412

Internet

https://doi.org/10.1002/rth2.12412

Similar Items